Company: SMNR
Filing Date: 2025-07-23
Form Type: S-4/A
Source: 0001193125-25-163401
Chunk: 842

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-23
Form: S-4/A
Chunk 842
---
 an aggregate of 40,000,000 shares of the Company’s common stock were considered anti-dilutive and therefore were excluded from the F-83

#### computation of diluted net loss per share for the year ended December 31, 2024. There were no outstanding securities considered anti-dilutive for computation of diluted net loss per share for the year ended December 31, 2024.Year Ended December 31,20242023Net loss (in thousands)$(4,690)$(3,261)Net loss per share — basic and diluted$(0.03)$(0.02)Weighted average number of shares during the period — basic and diluted160,000,000160,000,000Note 11. Subsequent EventsThe Company has completed an evaluation of all subsequent events through the date these financial statements were issued, to ensure these financial statements include appropriate disclosure of events both recognized in the financial statements and events which occurred but were not recognized in the financial statements. The Company has concluded that no events or transactions have occurred that require disclosure.F-84

#### SEMNUR PHARMACEUTICALS, INC.CONDENSED BALANCE SHEETS(In thousands, except for par value and share amounts)(Unaudited)March 31,2025December 31,2024ASSETSCurrent assets:Cash and cash equivalents$7$12Prepaid expenses—2Other current assets6,8175,981Total current assets:6,8245,995Property and equipment, net689689Total assets$7,513$6,684LIABILITIES AND STOCKHOLDERS’ DEFICITCurrent liabilities:Accrued expenses$207$35Total current liabilities:20735Related party loans50,75549,433Total liabilities50,96249,468Commitments and contingencies (See Note 6)Stockholders’ deficit:Preferred stock, $0.00001 par value, 45,000,000 shares authorized, and no shares issued and outstanding as of March 31, 2025 and December 31, 2024——Common stock, $0.00001 par value, 200,000,000 shares authorized, and 160,000,000 shares issued and outstanding as of March 31, 2025 and December 31, 202422Additionalpaid-incapital72,59872,598Accumulated deficit(116,049)(115,384)Total stockholders’ deficit(43,449)(42,